Summary (2)

• Genotype 1

• 51% SVR achieved with 48 weeks treatment, 1000/1200 mg RBV
  
• Shorter duration and/or lower RBV dose leads to reduction in efficacy

Previous slide

Next slide

Back to first slide

View graphic version

Shows that for Non-1 not only do you not apparently gain efficacy by ëincreasingí treatment but you also take on additional safety concerns